Ka Wai Ng, Nandita Chaturvedi, Gerard L. Coté, Stephanie A. Fisher, Samuel Mabbott
{"title":"治疗子痫前期的生物标志物和护理点筛查方法。","authors":"Ka Wai Ng, Nandita Chaturvedi, Gerard L. Coté, Stephanie A. Fisher, Samuel Mabbott","doi":"10.1038/s43856-024-00642-4","DOIUrl":null,"url":null,"abstract":"Preeclampsia is a multi-organ pregnancy complication, that is primarily detected when pregnant people have high blood pressure, and is confirmed by testing for the presence of protein in the urine. While more specific and accurate diagnostic and imaging tests are becoming available, they are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care. Since biochemical processes are a precursor to the systemic progression of disease, we review some established, emerging, and promising biomarkers that are proposed to be associated with preeclampsia, and newly developed approaches for screening them at the point of care, to reduce the burden of the disease. Ng, Chaturvedi et al. discuss established, emerging, and promising biomarkers related to preeclampsia. They highlight novel approaches for screening these biomarkers at the point of care, aiming to democratize testing and reduce the burden of the disease.","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493996/pdf/","citationCount":"0","resultStr":"{\"title\":\"Biomarkers and point of care screening approaches for the management of preeclampsia\",\"authors\":\"Ka Wai Ng, Nandita Chaturvedi, Gerard L. Coté, Stephanie A. Fisher, Samuel Mabbott\",\"doi\":\"10.1038/s43856-024-00642-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Preeclampsia is a multi-organ pregnancy complication, that is primarily detected when pregnant people have high blood pressure, and is confirmed by testing for the presence of protein in the urine. While more specific and accurate diagnostic and imaging tests are becoming available, they are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care. Since biochemical processes are a precursor to the systemic progression of disease, we review some established, emerging, and promising biomarkers that are proposed to be associated with preeclampsia, and newly developed approaches for screening them at the point of care, to reduce the burden of the disease. Ng, Chaturvedi et al. discuss established, emerging, and promising biomarkers related to preeclampsia. They highlight novel approaches for screening these biomarkers at the point of care, aiming to democratize testing and reduce the burden of the disease.\",\"PeriodicalId\":72646,\"journal\":{\"name\":\"Communications medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493996/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Communications medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s43856-024-00642-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communications medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s43856-024-00642-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Biomarkers and point of care screening approaches for the management of preeclampsia
Preeclampsia is a multi-organ pregnancy complication, that is primarily detected when pregnant people have high blood pressure, and is confirmed by testing for the presence of protein in the urine. While more specific and accurate diagnostic and imaging tests are becoming available, they are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care. Since biochemical processes are a precursor to the systemic progression of disease, we review some established, emerging, and promising biomarkers that are proposed to be associated with preeclampsia, and newly developed approaches for screening them at the point of care, to reduce the burden of the disease. Ng, Chaturvedi et al. discuss established, emerging, and promising biomarkers related to preeclampsia. They highlight novel approaches for screening these biomarkers at the point of care, aiming to democratize testing and reduce the burden of the disease.